Online inquiry

IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4812MR)

This product GTTS-WQ4812MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD4 gene. The antibody can be applied in Psoriasis, Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000616.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 920
UniProt ID P01730
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4812MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10940MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MBG-453
GTTS-WQ15445MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA U3-1287
GTTS-WQ2466MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 181
GTTS-WQ6304MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CS-1008
GTTS-WQ11018MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MCLA-117
GTTS-WQ10601MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LY3300054
GTTS-WQ6504MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CX-072
GTTS-WQ5913MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CIM 331
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW